(Q38132688)

29 August 2017

title

Chronic inflammation and cancer: suppressing the suppressors (English)

1 reference

29 August 2017

Michal Baniyash

1

1 reference

29 August 2017

Moshe Sade-Feldman

series ordinal

2

1 reference

29 August 2017

Julia Kanterman

series ordinal

3

1 reference

29 August 2017

publication date

29 August 2013

1 reference

Cancer Immunology, Immunotherapy

29 August 2017

published in

1 reference

29 August 2017

volume

63

1 reference

29 August 2017

issue

1

1 reference

29 August 2017

page(s)

11-20

1 reference

TCR zeta-chain downregulation: curtailing an excessive inflammatory immune response

29 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1468-9

Alterations in the expression of signal-transducing CD3 zeta chain in T cells from patients with chronic inflammatory/autoimmune diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1468-9

A common pathway mediated through Toll-like receptors leads to T- and natural killer-cell immunosuppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1468-9

Sustained exposure to bacterial antigen induces interferon-γ-dependent T cell receptor ζ down-regulation and impaired T cell function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1468-9

Myeloid-derived suppressor cells as regulators of the immune system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1468-9

Inflammation enhances myeloid-derived suppressor cell cross-talk by signaling through Toll-like receptor 4

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1468-9

Tumor necrosis factor-α blocks differentiation and enhances suppressive activity of immature myeloid cells during chronic inflammation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1468-9

Inflammation induces myeloid-derived suppressor cells that facilitate tumor progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1468-9

High-dose granulocyte-macrophage colony-stimulating factor-producing vaccines impair the immune response through the recruitment of myeloid suppressor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1468-9

Abrogation of TGF beta signaling in mammary carcinomas recruits Gr-1+CD11b+ myeloid cells that promote metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1468-9

TNF signaling drives myeloid-derived suppressor cell accumulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1468-9

Myeloid suppressor cells and immune modulation in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1468-9

An endotoxin-induced serum factor that causes necrosis of tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1468-9

Tumor necrosis factor therapy and the risk of serious infection and malignancy in patients with early rheumatoid arthritis: a meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1468-9

Anti-tumor necrosis factor and postoperative complications in Crohn's disease: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1468-9

Chronic inflammation promotes myeloid-derived suppressor cell activation blocking antitumor immunity in transgenic mouse melanoma model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1468-9

Pathways mediating the expansion and immunosuppressive activity of myeloid-derived suppressor cells and their relevance to cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1468-9

Tumor-induced tolerance and immune suppression by myeloid derived suppressor cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1468-9

Role of myeloid-derived suppressor cells in tumor immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1468-9

New insights into chronic inflammation-induced immunosuppression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1468-9

Myeloid derived suppressor cells and their role in tolerance induction in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1468-9

Restoration of antitumor immunity through selective inhibition of myeloid derived suppressor cells by anticancer therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1468-9

Blockade of myeloid-derived suppressor cells after induction of lymphopenia improves adoptive T cell therapy in a murine model of melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1468-9

The anticancer immune response: indispensable for therapeutic success?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1468-9

Myeloid suppressor cell depletion augments antitumor activity in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1468-9

Clinical perspectives on targeting of myeloid derived suppressor cells in the treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1468-9

The biology of myeloid-derived suppressor cells: the blessing and the curse of morphological and functional heterogeneity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1468-9

Increased myeloid-derived suppressor cells in gastric cancer correlate with cancer stage and plasma S100A8/A9 proinflammatory proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1468-9

Sunitinib-induced myeloid lineage redistribution in renal cell cancer patients: CD1c+ dendritic cell frequency predicts progression-free survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1468-9

Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1468-9

Combined vaccine+axitinib therapy yields superior antitumor efficacy in a murine melanoma model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1468-9

5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1468-9

Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1468-9

Chemotherapy-triggered cathepsin B release in myeloid-derived suppressor cells activates the Nlrp3 inflammasome and promotes tumor growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1468-9

Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1468-9

Cyclophosphamide promotes chronic inflammation-dependent immunosuppression and prevents antitumor response in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1468-9

Premetastatic soil and prevention of breast cancer brain metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1468-9

Anti-Gr-1 antibody depletion fails to eliminate hepatic myeloid-derived suppressor cells in tumor-bearing mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1468-9

COX-2 inhibition improves immunotherapy and is associated with decreased numbers of myeloid-derived suppressor cells in mesothelioma. Celecoxib influences MDSC function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1468-9

Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1468-9

Icariin and its derivative, ICT, exert anti-inflammatory, anti-tumor effects, and modulate myeloid derived suppressive cells (MDSCs) functions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1468-9

Icariin Derivative Inhibits Inflammation through Suppression of p38 Mitogen-Activated Protein Kinase and Nuclear Factor-.KAPPA.B Pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1468-9

Vemurafenib reverses immunosuppression by myeloid derived suppressor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1468-9

Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1468-9

All-trans-retinoic acid improves differentiation of myeloid cells and immune response in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1468-9

Paclitaxel promotes differentiation of myeloid-derived suppressor cells into dendritic cells in vitro in a TLR4-independent manner

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1468-9

A novel chemoimmunomodulating property of docetaxel: suppression of myeloid-derived suppressor cells in tumor bearers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1468-9

Chemoimmunomodulation of MDSCs as a novel strategy for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1468-9

10.1007/S00262-013-1468-9

21 January 2018

Identifiers

DOI

1 reference

Dimensions Publication ID

29 August 2017

1005198827

0 references

Fatcat ID

release_qenegitd7ze6tkiesmy24ujnn4

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/qenegitd7ze6tkiesmy24ujnn4

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference